Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.28 EUR | +3.49% | +2.06% | -0.52% |
Apr. 17 | Evotec Names First Chief People Officer | MT |
Apr. 12 | Corbion Appoints Barry Callebaut Chief Human Resources Officer to Same Role | MT |
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.52% | 1.22B | B+ | ||
+11.47% | 63.22B | A- | ||
-3.47% | 46.34B | A- | ||
+13.72% | 39.97B | B+ | ||
+17.83% | 25.46B | A- | ||
+7.27% | 18.68B | C+ | ||
-0.57% | 17.24B | B+ | ||
-21.73% | 15.81B | A- | ||
+0.22% | 14.9B | B+ | ||
-19.10% | 13.74B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CRBN Stock
- Ratings Corbion N.V.